USD 0.59
(-0.45%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -22.82 Million USD | 18.72% |
2022 | -24.23 Million USD | -7.74% |
2021 | -24.45 Million USD | -3.1% |
2020 | -23.91 Million USD | -26.86% |
2019 | -18.59 Million USD | -38.12% |
2018 | -14.42 Million USD | 15.32% |
2017 | -16.4 Million USD | -91.89% |
2016 | -8.2 Million USD | 16.43% |
2015 | -9.86 Million USD | 0.64% |
2014 | -10.42 Million USD | -188.11% |
2013 | -3.71 Million USD | 0.0% |
2012 | - USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -5.66 Million USD | 0.74% |
2024 Q2 | -5.59 Million USD | 1.13% |
2023 Q1 | -5.35 Million USD | 23.59% |
2023 Q2 | -5.92 Million USD | -10.6% |
2023 Q4 | -5.64 Million USD | 7.94% |
2023 Q3 | -6.13 Million USD | -3.53% |
2023 FY | - USD | 18.72% |
2022 Q2 | -5.69 Million USD | 38.39% |
2022 Q1 | -9.24 Million USD | -37.7% |
2022 FY | - USD | -7.74% |
2022 Q4 | -7.01 Million USD | -34.0% |
2022 Q3 | -5.23 Million USD | 8.14% |
2021 Q3 | -6.68 Million USD | -45.04% |
2021 Q4 | -6.71 Million USD | -0.48% |
2021 FY | - USD | -3.1% |
2021 Q2 | -4.6 Million USD | 38.44% |
2021 Q1 | -7.48 Million USD | -15.34% |
2020 FY | - USD | -26.86% |
2020 Q3 | -5.41 Million USD | 2.76% |
2020 Q2 | -5.56 Million USD | 24.93% |
2020 Q1 | -7.42 Million USD | -29.36% |
2020 Q4 | -6.48 Million USD | -19.81% |
2019 Q3 | -4.37 Million USD | 18.01% |
2019 Q1 | -3.9 Million USD | 4.78% |
2019 FY | - USD | -38.12% |
2019 Q4 | -5.73 Million USD | -31.25% |
2019 Q2 | -5.33 Million USD | -36.37% |
2018 Q4 | -4.1 Million USD | -41.66% |
2018 FY | - USD | 15.32% |
2018 Q3 | -2.89 Million USD | 13.55% |
2018 Q1 | -4.07 Million USD | 11.18% |
2018 Q2 | -3.35 Million USD | 17.71% |
2017 Q4 | -4.58 Million USD | -35.81% |
2017 FY | - USD | -91.89% |
2017 Q3 | -3.37 Million USD | 14.8% |
2017 Q2 | -3.96 Million USD | 11.44% |
2017 Q1 | -4.47 Million USD | -75.39% |
2016 Q2 | -1.6 Million USD | 27.77% |
2016 Q4 | -2.55 Million USD | -40.09% |
2016 Q3 | -1.82 Million USD | -13.36% |
2016 Q1 | -2.22 Million USD | 19.73% |
2016 FY | - USD | 16.43% |
2015 FY | - USD | 0.64% |
2015 Q4 | -2.77 Million USD | -29.1% |
2015 Q3 | -2.14 Million USD | 10.26% |
2015 Q2 | -2.39 Million USD | 6.48% |
2015 Q1 | -2.55 Million USD | 22.73% |
2014 Q1 | -2.11 Million USD | -17.53% |
2014 Q4 | -3.31 Million USD | -28.61% |
2014 Q2 | -2.41 Million USD | -13.7% |
2014 FY | - USD | -188.11% |
2014 Q3 | -2.57 Million USD | -6.8% |
2013 Q3 | -1.45 Million USD | -327.64% |
2013 Q2 | -339.79 Thousand USD | -203.03% |
2013 Q1 | -112.13 Thousand USD | 0.0% |
2013 Q4 | -1.8 Million USD | -24.11% |
2013 FY | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
AIM ImmunoTech Inc. | -31.67 Million USD | 27.947% |
Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
Armata Pharmaceuticals, Inc. | -39.91 Million USD | 42.82% |
Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 55.359% |
Azitra, Inc. | -10.67 Million USD | -113.854% |
Can-Fite BioPharma Ltd. | -8.18 Million USD | -179.034% |
Chromocell Therapeutics Corporation | -6.86 Million USD | -232.615% |
Calidi Biotherapeutics, Inc. | -28.6 Million USD | 20.192% |
CEL-SCI Corporation | -27.56 Million USD | 17.182% |
iBio, Inc. | -14.02 Million USD | -62.792% |
Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 7.714% |
MAIA Biotechnology, Inc. | -20.18 Million USD | -13.094% |
Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -64.503% |
NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -375.521% |
NanoViricides, Inc. | -7.75 Million USD | -194.247% |
Oragenics, Inc. | -20.87 Million USD | -9.328% |
BiomX Inc. | -22.81 Million USD | -0.044% |
BiomX Inc. | -22.81 Million USD | -0.044% |
Protalix BioTherapeutics, Inc. | 11.65 Million USD | 295.906% |
Palatin Technologies, Inc. | -29.03 Million USD | 21.378% |
Scorpius Holdings, Inc. | -35.08 Million USD | 34.939% |